PCSK9 and familial hypercholesterolemia: Considering the currently available data in its totality (Table 1), PCSK9 antibodies present a revolutionary therapeutic option that could benefit a wide-range of patients, such as those with familial hypercholesterolemia, patients with statin intolerance and patients at high or very high cardiovascular risk that cannot achieve their LDL-C target levels with the currently available lipid-lowering therapies.